Key facts
- This page summarizes Christine Ring's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Dec 2021, 15:47.
Christine Ring - 10 Dec 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)
- Reporting relationship
- General Counsel
- Issuer ticker
- NRIX
- Reported as of
- 10 Dec 2021
- Net transaction value
- -$32,616
- SEC form
- 4
- Accepted by SEC
- 13 Dec 2021, 15:47:31 UTC
- Prior SEC filing
- 12 Nov 2021
- Next SEC filing
- 11 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christine Ring
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christine Ring filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 13 Dec 2021.
Change
- Previous filing in this sequence was filed on 12 Nov 2021.
- Current net transaction value: -$32,616.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NRIX
transaction
Common Stock
Options Exercise
- Transaction value
- $2,232
- Shares
- +1,200
- Change %
- +93%
- Price
- $1.86*
- Shares after
- 2,486
- Date
- 10 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
NRIX
transaction
Common Stock
Sale
- Transaction value
- $34,848
- Shares
- -1,200
- Change %
- -48%
- Price
- $29.04
- Shares after
- 1,286
- Date
- 10 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NRIX
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,200
- Change %
- -1.2%
- Price
- $0.000000
- Shares after
- 101,266
- Date
- 10 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,200
- Exercise price
- $1.86
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Footnote F2
The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.